Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to
more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to
develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully
develop its hematology / oncology and
inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Pressure ulcers affect
more than 2.5 million Americans annually and patients who have spinal cord injuries that impair movement are
more vulnerable to
developing them, said senior investigator Yoram Vodovotz, Ph.D., professor of surgery and director of the Center for
Inflammation and Regenerative Modeling at the Pitt School of Medicine.
The scientists transferred the twins» gut bacteria to mice predisposed to
develop a disease that mimics MS. Twelve weeks after the transplant, about 40 percent
more mice with gut microbes from a twin with MS
developed brain
inflammation compared with mice that got gut microbes from a twin without disease.
Rheumatoid arthritis patients are likelier than the average person to
develop chronic kidney disease, and
more severe
inflammation in the first year of rheumatoid arthritis, corticosteroid use, high blood pressure and obesity are among the risk factors, new Mayo Clinic research shows.
Pathogenic bacterial infections like salmonella and E. coli are huge problems in
developing countries because they are much
more harmful to people suffering from malnutrition, leading to chronic diarrhea and
inflammation.
After downing his bacterial concoction, he soon became far
more ill than he had expected, vomiting and
developing stomach
inflammation.
10 Possible explanation: Pregnant women tend to
develop gingivitis (
inflammation of the gums) as hormonal shifts make the tissues
more sensitive to irritation.
Bettcher said the new findings could possibly serve as the focus of
more in - depth studies aimed at
developing a blood test to detect
inflammation biomarkers years before symptoms of Alzheimer's appear.
Chronically sleep deprived people are
more likely to
develop other health problems such as increased
inflammation and high blood pressure.
Grn − / −, but not Grn + / − mice,
develop progressive gliosis,
inflammation, and lipofuscinosis in several brain regions that first becomes detectable around 6 — 7 months of age and is
more strongly elevated by 12 months (Ahmed et al., 2010; Yin et al., 2010; Wils et al., 2012; Filiano et al., 2013; Götzl et al., 2014).
«Work needs to be done to uncover the specific factors that contribute to brain
inflammation, but finding a way to reduce
inflammation's harmful effects and increase its helpful effects could enable us to
develop a new treatment much
more quickly,» Meyer concluded.
A healthy microbiome means a person has a better immune system, less risk of
developing an auto - immune disease, reduced
inflammation, are
more insulin sensitive, and perhaps can be happier with less depression and anxiety, since studies do show a «brain - gut» connection.
To understand
more about why people
develop Alzheimer's disease, Dr. Lewis recommends looking to the various causes of
inflammation, which can include environmental toxins, stress, poor nutrition, lack of sleep and bacterial and viral infections.
I have increasingly
developed more and
more food sensitivities that result in swelling finger joints and eruptions on facial skin, and I would suspect general
inflammation.
Factors like this, in addition to culprits like undiagnosed food allergies and foods that are loaded with sugar and fat can cause
inflammation to
develop throughout the entire body, and
more often than not the result of this will become evident on the skin.
Chronic stress while the brain and central nervous system are still
developing can create ongoing
inflammation and set the stage for autoimmune disease to
more easily trigger later in life.
By eating
more of certain foods, many of which are perfect in smoothie recipes, and avoiding bad foods, you can lower your overall
inflammation and reduce your risk of
developing some of these diseases.
Experiments in Muc1 knockout mice and mice with Muc1 knockdown have shown that under Helicobacter infection, mice deficient in Muc1
develop far
more cancer - promoting
inflammation than normal mice.
Pets that eat hard kibble
develop this tartar and
inflammation more slowly.
In
more serious — but fortunately, less common — cases, dogs can
develop a type of kidney disease called Lyme nephritis, which is often fatal, even in young, healthy dogs, as well as myocarditis —
inflammation of the heart muscle — and neurological disease.
Dogs and cats are
more likely to
develop heat and
inflammation of the ears, head, neck, and feet than of the eyes and nose.
Because dogs» eyes
develop more serious
inflammation than human eyes after cataract surgery, they must receive treatments (a combination of pills, eye drops, and ointments) several times daily for four to six weeks after this surgery.
This is
more often seen in older rabbits, as these have had time to
develop molar spurs, or molar root problems that can cause
inflammation or even
develop into infections that spread to the sinuses.
The healthy mice
developed low - grade intestinal
inflammation and a metabolic disorder that caused them to eat
more, becoming obese, hyperglycemic, and resistant to insulin.